LYM
MCID: LYM017
MIFTS: 64

Lyme Disease (LYM)

Categories: Infectious diseases, Neuronal diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Lyme Disease

MalaCards integrated aliases for Lyme Disease:

Name: Lyme Disease 11 19 42 58 75 53 41 2 43 14 16 71 31 33
Lyme Borreliosis 11 19 42 58 14 33
Lyme Neuroborreliosis 11 53 43 71 33
Borrelia Burgdorferi Infection 42 2 33
Borreliosis 19 75 53
Neuroborreliosis 11 71
Infection Due to Borrelia Burgdorferi Sensu Lato 42
Infection by Borrelia Burgdorferi 42
Neurological Lyme Disease 11
B. Burgdorferi Infection 42
Bannworth's Syndrome 11
Borrelia Infections 71
Bannwarth Syndrome 11
Borreliosis, Lyme 42
Lym 75

Characteristics:


Prevelance:

>1/1000 (Europe, United States) 1-5/10000 (France, Hungary) 58

Age Of Onset:

All ages 58

Classifications:

Orphanet: 58  
Rare neurological diseases
Rare infectious diseases


External Ids:

Disease Ontology 11 DOID:11729
ICD9CM 34 088.81
NCIt 49 C45161
SNOMED-CT 68 154376000 715507005
ICD10 31 A69.2
MESH via Orphanet 44 D008193
ICD10 via Orphanet 32 A69.2
UMLS via Orphanet 72 C0024198
Orphanet 58 ORPHA91546
UMLS 71 C0006035 C0024198 C0752235 more

Summaries for Lyme Disease

MedlinePlus: 41 What is Lyme disease? Lyme disease is a bacterial infection you get from the bite of an infected tick. At first, Lyme disease usually causes symptoms such as a rash, fever, headache, and fatigue. But if it is not treated early, the infection can spread to your joints, heart, and nervous system. Prompt treatment can help you recover quickly. What causes Lyme disease? Lyme disease is caused by bacteria. In the United States, this is usually a bacterium called Borrelia burgdorferi. It spreads to humans through the bite of an infected tick. The ticks that spread it are blacklegged ticks (or deer ticks). They are usually found in the: Northeast Mid-Atlantic Upper Midwest Pacific coast, especially northern California These ticks can attach to any part your body. But they are often found in hard-to-see areas such as your groin, armpits, and scalp. Usually the tick must be attached to you for 36 to 48 hours or more to spread the bacterium to you. Who is at risk for Lyme disease? Anyone can get a tick bite. But people who spend lots of time outdoors in wooded, grassy areas are at a higher risk. This includes campers, hikers, and people who work in gardens and parks. Most tick bites happen in the summer months when ticks are most active and people spend more time outdoors. But you can get bitten in the warmer months of early fall, or even late winter if temperatures are unusually high. And if there is a mild winter, ticks may come out earlier than usual. What are the symptoms of Lyme disease? Early symptoms of Lyme disease start between 3 to 30 days after an infected tick bites you. The symptoms can include: A red rash called erythema migrans (EM). Most people with Lyme disease get this rash. It gets bigger over several days and may feel warm. It is usually not painful or itchy. As it starts to get better, parts of it may fade. Sometimes this makes the rash look like a "bull's-eye." Fever Chills Headache Fatigue Muscle and joint aches Swollen lymph nodes If the infection is not treated, it can spread to your joints, heart, and nervous system. The symptoms may include: Severe headaches and neck stiffness Additional EM rashes on other areas of your body Facial palsy, which is a weakness in your facial muscles. It can cause drooping on one or both sides of your face. Arthritis with severe joint pain and swelling, especially in your knees and other large joints Pain that comes and goes in your tendons, muscles, joints, and bones Heart palpitations, which are feelings that your heart is skipping a beat, fluttering, pounding, or beating too hard or too fast An irregular heart beat (Lyme carditis) Episodes of dizziness or shortness of breath Inflammation of the brain and spinal cord Nerve pain Shooting pains, numbness, or tingling in the hands or feet How is Lyme disease diagnosed? To make a diagnosis, your health care provider will consider: Your symptoms How likely it is that you were exposed to infected blacklegged ticks The possibility that other illnesses may cause similar symptoms Results of any lab tests Most Lyme disease tests check for antibodies made by the body in response to infection. These antibodies can take several weeks to develop. If you are tested right away, it may not show that you have Lyme disease, even if you have it. So you may need to have another test later. What are the treatments for Lyme disease? Lyme disease is treated with antibiotics. The earlier you are treated, the better; it gives you the best chance of fully recovering quickly. After treatment, some patients may still have pain, fatigue, or difficulty thinking that lasts more than 6 months. This is called post-treatment Lyme disease syndrome (PTLDS). Researchers don't know why some people have PTLDS. There is no proven treatment for PTLDS; long-term antibiotics have not been shown to help. However, there are ways to help with the symptoms of PTLDS. If you have been treated for Lyme disease and still feel unwell, contact your health care provider about how to manage your symptoms. Most people do get better with time. But it can take several months before you feel all better. Can Lyme disease be prevented? To prevent Lyme disease, you should lower your risk of getting a tick bite: Avoid areas where ticks live, such as grassy, brushy, or wooded areas. If you are hiking, walk in the center of the trail to avoid brush and grass. Use an insect repellent with DEET Treat your clothing and gear with a repellant containing 0.5% permethrin Wear light-colored protective clothing, so you can easily see any ticks that get on you Wear a long-sleeve shirt and long pants. Also tuck your shirt into your pants and your pant legs into your socks. Check yourself, your children, and your pets daily for ticks. Carefully remove any ticks you find. Take a shower and wash and dry your clothes at high temperatures after being outdoors Centers for Disease Control and Prevention

MalaCards based summary: Lyme Disease, also known as lyme borreliosis, is related to babesiosis and mononeuritis multiplex, and has symptoms including fatigue, fever and headache. An important gene associated with Lyme Disease is YBX3 (Y-Box Binding Protein 3), and among its related pathways/superpathways are Innate Immune System and Disease. The drugs Amoxicillin and Phenoxymethylpenicillin have been mentioned in the context of this disorder. Affiliated tissues include heart, spinal cord and skin, and related phenotypes are arthritis and cranial nerve paralysis

MedlinePlus Genetics: 42 Lyme disease is an infectious disease caused by Borrelia burgdorferi bacteria. The bacteria are transferred to humans by tick bite, specifically by blacklegged ticks (commonly known as deer ticks). The condition is named for the location in which it was first described, the town of Lyme, Connecticut.If not treated with antibiotics, Lyme disease follows three stages: early localized, early disseminated, and late disseminated infection. A small percentage of individuals have symptoms that persist months or years after treatment, which is called post-treatment Lyme disease syndrome.A characteristic feature of Lyme disease, and the key feature of early localized infection, is a slowly expanding red rash on the skin (called erythema migrans) at the site of the tick bite; the rash is often bull's-eye shaped. Flu-like symptoms and enlarged lymph nodes (lymphadenopathy) are also early signs of infection. Most people who are treated at this stage never develop further symptoms.The early disseminated stage of Lyme disease occurs as the bacteria is carried throughout the body in the bloodstream. This stage occurs a few weeks after the tick bite. Signs and symptoms can include additional rashes on other parts of the body, flu-like symptoms, and lymphadenopathy. Some affected individuals develop neurologic problems (referred to as neuroborreliosis), such as paralyzed muscles in the face (facial palsy); pain, numbness, or weakness in the hands or feet; difficulty concentrating; or memory problems. Rarely, the heart is affected (Lyme carditis), causing a sensation of fluttering or pounding in the chest (palpitations) or an irregular heartbeat.The late disseminated stage of Lyme disease can occur months to years after the tick bite. The most common feature of this stage, Lyme arthritis, is characterized by episodes of joint pain and swelling, usually affecting the knees. In rare cases, the late disseminated stage also involves neurological problems.Individuals with post-treatment Lyme disease syndrome report ongoing exhaustion (fatigue), muscle and joint achiness, headache, or difficulty concentrating even after treatment with antibiotics, when there is no evidence of the bacteria in the body. Very rarely, individuals have joint pain and swelling for months or years after successful antibiotic treatment. This complication is called antibiotic-refractory Lyme arthritis.

CDC: 2 Lyme disease is caused by the bacterium Borrelia burgdorferi and is transmitted to humans through the bite of infected blacklegged ticks. Typical symptoms include fever, headache, fatigue, and a characteristic skin rash called erythema migrans. If left untreated, infection can spread to joints, the heart, and the nervous system. Lyme disease is diagnosed based on symptoms, physical findings (e.g., rash), and the possibility of exposure to infected ticks. Laboratory testing is helpful if used correctly and performed with validated methods. Most cases of Lyme disease can be treated successfully with a few weeks of antibiotics. Steps to prevent Lyme disease include using insect repellent, removing ticks promptly, applying pesticides, and reducing tick habitat. The ticks that transmit Lyme disease can occasionally transmit other tickborne diseases as well.

GARD: 19 Lyme disease is the most common tickborne infectious disease in the United States. Early signs and symptoms of the condition include fever, chills, muscle pain, headache, and joint pain. As the condition progresses, affected people may experience heart problems, Bell's palsy, arthritis, abnormal muscle movement, speech problems and cognitive (thinking) abnormalities. Please visit the Center for Disease Control and Prevention's Web site for a more comprehensive list of symptoms. Lyme disease is caused by the bacterium Borrelia burgdorferi, which is transmitted to humans through the bite of infected blacklegged ticks. Certain features of the condition, including whether or not an affected person will develop medication-resistant chronic arthritis, is thought to be influenced by genetic factors (certain human leukocyte antigen genes).

Disease Ontology: 11 A primary bacterial infectious disease that results in infection, has material basis in Borrelia burgdorferi, which is transmitted by blacklegged tick (Ixodes scapularis) or transmitted by western blacklegged tick (Ixodes pacificus). The infection has symptom fever, has symptom headache, has symptom fatigue, and has symptom skin rash called erythema migrans. If left untreated, infection can spread to joints, the heart, and the nervous system.

Orphanet: 58 Lyme disease (named after the towns in the USA where the disease was first identified) is a bacterial infection caused by Borrelia burgdorferi.

Wikipedia: 75 Lyme disease, also known as Lyme borreliosis, is a vector-borne disease caused by the Borrelia... more...

Related Diseases for Lyme Disease

Diseases related to Lyme Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1222)
# Related Disease Score Top Affiliating Genes
1 babesiosis 32.2 TNF HSPD1 CRP
2 mononeuritis multiplex 32.1 TNF HLA-DRB1 CRP
3 intermediate uveitis 32.0 TNF IL6 IL17A
4 bell's palsy 31.7 TNF IL6 CRP
5 relapsing fever 31.5 YBX3 TNF HSPD1 CRP CFHR1 CFH
6 facial paralysis 31.5 TNF IL6 CRP
7 exanthem 31.5 TNF IL6 IL1B IL17A CRP
8 neuritis 31.5 TNF IL6 IL1B
9 radiculopathy 31.3 IL6 IL17A CRP
10 syphilis 31.2 TNF TLR2 IL17A HLA-DRB1 CRP CD40LG
11 chronic fatigue syndrome 31.1 TNF IL6 IL1B CRP
12 acrodermatitis chronica atrophicans 31.1 YBX3 CD40LG
13 fibromyalgia 31.0 TNF IL6 IL1B CRP
14 mononeuropathy 31.0 TNF IL6 CRP
15 optic neuritis 31.0 TNF IL6 IL1B HLA-DRB1
16 myelitis 31.0 TNF IL6 IL17A IFNB1
17 myocarditis 30.9 TNF IL6 IL1B IL17A CD40LG
18 viral encephalitis 30.9 TNF IL6 IL1B IFNB1
19 encephalitis 30.9 TNF TLR2 IL6 IL1B IFNB1
20 aseptic meningitis 30.9 TNF IL6 IL1B CRP C4A
21 synovitis 30.9 TNF IL6 IL1B CRP
22 keratitis, hereditary 30.9 TNF TLR2 IL6 IL1B IL17A
23 viral meningitis 30.9 TNF IL6 CRP
24 uveitis 30.9 TNF IL6 IL1B IL17A HSPD1 HLA-DRB1
25 arthropathy 30.8 TNF IL6 IL1B CRP
26 localized scleroderma 30.8 TNF IL6 IL17A
27 erysipelas 30.8 TNF IL6 IL1B CRP
28 myositis 30.8 TNF IL6 IL1B IL17A HLA-DRB1
29 meningoencephalitis 30.8 TNF IL6 IL1B CRP CD40LG
30 bacterial meningitis 30.8 TNF TLR2 IL1B CRP
31 pericarditis 30.7 TNF IL6 IL1B CRP
32 neurosyphilis 30.7 TLR6 TLR2 TLR1 IL17A
33 guillain-barre syndrome 30.7 TNF IL17A HLA-DRB1 CD40LG
34 pfeiffer syndrome 30.6 TNF HLA-DRB1 CRP CD40LG
35 juvenile rheumatoid arthritis 30.6 TNF IL6 IL1B HSPD1 HLA-DRB1 CRP
36 periostitis 30.6 TNF IL1B CRP
37 osteoarthritis 30.6 TNF IL6 IL1B IL17A CRP
38 peripheral nervous system disease 30.6 TNF IL6 IL1B IL17A IFNB1 CRP
39 tick-borne relapsing fever 30.6 YBX3 HSPD1 CFHR1 C4A C3
40 intracranial hypertension 30.6 TNF IL6 IL1B CRP
41 leptospirosis 30.5 TNF TLR2 TLR1 IL6 IL1B CRP
42 optic papillitis 30.5 TNF CRP
43 transverse myelitis 30.5 TNF IL6 IFNB1 HLA-DRB1 CRP
44 pyuria 30.5 IL6 CRP C3
45 pericardial effusion 30.5 TNF IL6 CRP
46 rheumatic fever 30.5 TNF TLR2 IL6 HLA-DRB1
47 septic arthritis 30.5 TNF TLR2 IL6 IL1B IL17A HSPD1
48 cellulitis 30.5 TNF IL6 IL1B IL17A CRP
49 posterior uveitis 30.5 TNF IL6 IL17A
50 graves ophthalmopathy 30.5 TNF IL6 IL1B

Graphical network of the top 20 diseases related to Lyme Disease:



Diseases related to Lyme Disease

Symptoms & Phenotypes for Lyme Disease

Human phenotypes related to Lyme Disease:

58 30 (show all 25)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 arthritis 58 30 Frequent (33%) Frequent (79-30%)
HP:0001369
2 cranial nerve paralysis 58 30 Frequent (33%) Frequent (79-30%)
HP:0006824
3 joint swelling 58 30 Frequent (33%) Frequent (79-30%)
HP:0001386
4 meningitis 58 30 Frequent (33%) Frequent (79-30%)
HP:0001287
5 nausea and vomiting 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002017
6 muscle weakness 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001324
7 photophobia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000613
8 fatigue 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0012378
9 fever 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001945
10 atrioventricular block 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001678
11 arthralgia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002829
12 myalgia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0003326
13 arrhythmia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0011675
14 uveitis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000554
15 paresthesia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0003401
16 insomnia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0100785
17 peripheral neuropathy 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0009830
18 headache 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002315
19 memory impairment 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002354
20 amaurosis fugax 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0100576
21 dermal atrophy 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0004334
22 skin nodule 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0200036
23 infectious encephalitis 30 Occasional (7.5%) HP:0002383
24 encephalitis 58 Occasional (29-5%)
25 behavioral abnormality 58 Occasional (29-5%)

Symptoms:

11
  • fatigue
  • fever
  • headache
  • skin rash called erythema migrans

UMLS symptoms related to Lyme Disease:


fever; pruritus

GenomeRNAi Phenotypes related to Lyme Disease according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.19 C3 C4A CD40LG CFH CFHR1 CLDN11
2 no effect GR00402-S-2 10.19 C3 C4A CD40LG CFH CFHR1 CLDN11
3 Reduced mammosphere formation GR00396-S 9.56 C3 C4A CFHR1 CLDN11 HSPD1 IL17A

MGI Mouse Phenotypes related to Lyme Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.17 C3 C4A CD40LG CFH CLDN11 CRP
2 renal/urinary system MP:0005367 10.07 C3 C4A CD40LG CFH IL17A IL6
3 digestive/alimentary MP:0005381 9.91 C3 C4A IL17A IL6 TLR2 TLR7
4 cardiovascular system MP:0005385 9.9 C3 C4A CD40LG CFH CRP HSPD1
5 immune system MP:0005387 9.83 C3 C4A CD40LG CFH CRP IFNB1
6 hematopoietic system MP:0005397 9.5 C3 C4A CD40LG CFH HSPD1 IFNB1

Drugs & Therapeutics for Lyme Disease

Drugs for Lyme Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 65)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
2
Phenoxymethylpenicillin Approved, Vet_approved Phase 4 87-08-1 6869
3
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
4
Ceftriaxone Approved Phase 4 73384-59-5 5479530
5
Hydroxychloroquine Approved Phase 4 118-42-3 3652
6
Clarithromycin Approved Phase 4 81103-11-9 84029
7
Cefuroxime Approved Phase 4 55268-75-2 5479529
8
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
9
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
10
Prednisolone Approved, Vet_approved Phase 4 50-24-8 4894 5755
11
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5 1875
12
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 4159 6741
13
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7 4897
14
Cortisone Experimental Phase 4 53-06-5 222786
15 Anti-Bacterial Agents Phase 4
16 Anti-Infective Agents Phase 4
17 Antiprotozoal Agents Phase 4
18 Antiparasitic Agents Phase 4
19 Antimalarials Phase 4
20 Penicillins Phase 4
21 Cytochrome P-450 Enzyme Inhibitors Phase 4
22 Cytochrome P-450 CYP3A Inhibitors Phase 4
23
Cefuroxime axetil Phase 4 3379942
24 Anti-Inflammatory Agents Phase 4
25 Antineoplastic Agents, Hormonal Phase 4
26 Hormones Phase 4
27 Hormone Antagonists Phase 4
28 glucocorticoids Phase 4
29
Methylprednisolone Acetate Phase 4 584547
30
Acetaminophen Approved Phase 3 103-90-2 1983
31
Naproxen Approved, Vet_approved Phase 3 22204-53-1 156391 1302
32
Permethrin Approved, Investigational Phase 3 52645-53-1 40326
33 PENTA Phase 3
34 Antirheumatic Agents Phase 3
35 Analgesics Phase 3
36 Antipyretics Phase 3
37 Cyclooxygenase Inhibitors Phase 3
38 Anti-Inflammatory Agents, Non-Steroidal Phase 3
39 Analgesics, Non-Narcotic Phase 3
40 Vaccines Phase 3
41 Pharmaceutical Solutions Phase 3
42
Ethanol Approved Phase 1, Phase 2 64-17-5 702
43
Disulfiram Approved Phase 1, Phase 2 97-77-8 3117
44
Azithromycin Approved Phase 1, Phase 2 83905-01-5 447043
45
Aluminum sulfate Approved Phase 2 10043-01-3
46
Tetracycline Approved, Vet_approved, Withdrawn Phase 2 60-54-8 5353990
47 Vitamins Phase 1, Phase 2
48 Immunologic Factors Phase 1, Phase 2
49
Aluminum hydroxide Approved, Investigational Phase 1 21645-51-2
50
Psilocybin Investigational Phase 1 520-52-5

Interventional clinical trials:

(show top 50) (show all 78)
# Name Status NCT ID Phase Drugs
1 Tick Borne Diseases in Norwegian General Practice. A Randomized, Controlled Trial for Treatment of Erythema Migrans in Norwegian General Practice. A Comparison of Phenoxymethylpenicillin, Amoxicillin and Doxycycline. Completed NCT01368341 Phase 4 Doxycycline;Phenoxymethylpenicillin;Amoxicillin
2 Persistent Lyme Empiric Antibiotic Study Europe. A Prospective, Randomised Study Comparing Two Prolonged Oral Antibiotic Strategies After Initial Intravenous Ceftriaxone Therapy for Patients With Symptoms of Proven or Possible Persistent Lyme Disease Completed NCT01207739 Phase 4 Doxycycline;Clarithromycin and hydroxychloroquine;Placebo
3 Risk Factors for Failure of Erythema Migrans Treatment - Comparison of Doxycycline and Cefuroxime Axetil for Treatment of Adult Patients With Erythema Migrans: Clinical and Microbiological Outcome. Completed NCT01518192 Phase 4 doxycycline;cefuroxime axetil
4 Study of Lyme Neuroborreliosis: Epidemiology, Manifestations, Diagnostics and Treatment Completed NCT01635530 Phase 4 Doxycycline;Ceftriaxone
5 The Facial Nerve Palsy And Cortisone Evaluation (FACE) Study in Children: A Randomized Double-blind, Placebo-controlled, Multicenter Trial Recruiting NCT03781700 Phase 4 Prednisolone;Placebo Oral Tablet
6 A Novel Nutraceutical to Combat Post-Lyme Disease Syndrome Completed NCT04141969 Phase 2, Phase 3
7 A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of the Safety and Efficacy of Ceftriaxone and Doxycycline in the Treatment of Patients With Seropositive Chronic Lyme Disease Completed NCT00001101 Phase 3 ceftriaxone;doxycycline
8 A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of the Safety and Efficacy of Ceftriaxone and Doxycycline in the Treatment of Patients With Seronegative Chronic Lyme Disease Completed NCT00000938 Phase 3 ceftriaxone;doxycycline
9 A Controlled Trial of a Primary and Secondary Program for Lyme Disease Completed NCT00000432 Phase 3
10 Study and Treatment of Post Lyme Disease (STOP-LD) Completed NCT00000937 Phase 3 Antibiotics
11 Effect of Intravenous Ceftriaxone and Oral Doxycycline for Lyme Neuroborreliosis. A Randomized Double-blind Comparison Completed NCT00138801 Phase 3 Ceftriaxone;Doxycycline
12 Six Versus Two Weeks Treatment With Doxycycline in Lyme Neuroborreliosis; a Multicenter, Non-inferiority, Penta-blind, Randomized Trial Completed NCT02553473 Phase 3 Doxycycline;Placebo
13 A Phase 3, Multicenter, Placebo-Controlled, Randomized, Observer-Blinded Trial to Evaluate the Efficacy, Safety, Tolerability, Immunogenicity, and Lot Consistency of a 6-Valent OspA-Based Lyme Disease Vaccine in Healthy Participants ≥5 Years of Age Recruiting NCT05477524 Phase 3
14 Symptomatic Management of Lyme Arthritis Recruiting NCT04038346 Phase 3 Naproxen;Acetaminophen
15 A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLINDED TRIAL TO EVALUATE THE SAFETY OF A 6-VALENT OspA-BASED LYME DISEASE VACCINE (VLA15) IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE Not yet recruiting NCT05634811 Phase 3
16 Passive Prophylaxis of Lyme Disease Using Permethrin Treated Clothes Terminated NCT00958139 Phase 3
17 Using ReaLife+ to Treat Post-Lyme Disease Syndrome Completed NCT04078841 Phase 1, Phase 2
18 Disulfiram ("Antabuse"): A Test of Symptom Reduction Among Patients With Previously Treated Lyme Disease Completed NCT03891667 Phase 1, Phase 2 Disulfiram
19 Xenodiagnosis After Antibiotic Treatment for Lyme Disease - Phase II Study Completed NCT02446626 Phase 1, Phase 2
20 PET and MRI Imaging of Persistent Lyme Encephalopathy Completed NCT00037479 Phase 2 ceftriaxone
21 A Single Centre, Randomized, Investigator Blinded, Placebo-controlled Ascending Dose Study to Assess the Local Safety, the Skin and Plasma Concentration of Azithromycin Dermal Formulation During Repeated Applications on the Skin of Healthy Volunteers Completed NCT01243008 Phase 1, Phase 2 Application of SHB001
22 Immunogenicity and Safety Study of VLA15, A Multivalent Recombinant OspA (Outer Surface Protein A) Based Vaccine Candidate Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years. A Randomized, Controlled, Observer-blind Phase 2 Study. Completed NCT03769194 Phase 2
23 Randomized, Double-Blind, Phase 1/2 Clinical Study to Investigate the Safety and Immunogenicity of a Multivalent Recombinant OspA Lyme Borreliosis Vaccine (mv rOspA LB Vaccine) in Healthy Subjects Aged 18 to 70 Years Completed NCT01504347 Phase 1, Phase 2
24 Investigating the Human Immune Response to Ixodes Scapularis Tick Bites Recruiting NCT05036707 Phase 1, Phase 2
25 Safety And Immunogenicity Study Of VLA15, A Multivalent Recombinant OspA Based Vaccine Candidate Against Lyme Borreliosis: A Randomized, Controlled, Observer-Blind Phase 2 Study In A Healthy Pediatric And Adult Study Population Active, not recruiting NCT04801420 Phase 2
26 Alternative Schedule Study For VLA15, A Multivalent Recombinant OspA (Outer Surface Protein A) Based Vaccine Candidate Against Lyme Borreliosis, In Healthy Adults Aged 18 To 65 Years - A Randomized, Controlled, Observer-Blind Phase 2 Study Active, not recruiting NCT03970733 Phase 2
27 T4 - Tetracycline Treatment Tolerability Trial A Pilot Study Examining the Feasibility and Tolerability of Tetracycline Therapy in Post-Treatment Lyme Disease (PTLD) Enrolling by invitation NCT05219929 Phase 2 Tetracycline 500 Mg
28 A Phase 1 Study in Healthy Subjects to Evaluate the Safety and Pharmacokinetics of a Human Monoclonal Antibody (2217LS) Against Borrelia Burgdorferi (B. Burgdorferi) Outer Surface Protein A (OspA) Completed NCT04863287 Phase 1
29 Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Multivalent Recombinant OspA Vaccine Candidate Against Lyme Borreliosis, In Healthy Adults Aged Below 40 Years Completed NCT03010228 Phase 1
30 Effects of Psilocybin in Post-Treatment Lyme Disease Enrolling by invitation NCT05305105 Phase 1 Psilocybin
31 Meditation and Stretching for Post Treatment Lyme Disease Syndrome Unknown status NCT02344537
32 Comparative Study of Peripheral Facial Paralysis Sequelae Based on the Initial Medical Care of Lyme Disease Among Children Unknown status NCT03981874
33 Novel Diagnostics for Early Lyme Disease Unknown status NCT03963635
34 One-Health Approach to Identify Threat Posed by Tick-borne Pathogens Responsible of Unexplained Infectious Syndrome in Humans Unknown status NCT03501407
35 Clinical and Microbiological Parameters in Patients With Early Lyme Neuroborreliosis Unknown status NCT00910533 ceftriaxone
36 Characteristics of Positive Lyme PCR Arthritis, Data From CNR Borrelia 2011-2016 Unknown status NCT03510507
37 An Intervention in a Primary Healthcare Setting to Reduce Lyme Neuroborreliosis Treatment Delay Unknown status NCT03820999
38 Doxycycline and Ceftriaxone in Patients With Suspected Early Lyme Neuroborreliosis and Normal CSF Cell Count. Unknown status NCT00942006 doxycycline;ceftriaxone
39 Next Generation Sequencing to Detect Borrelia Burgdorferi DNA in the Blood of Pediatric Patients With Lyme Disease Completed NCT03505879
40 A School-Based Intervention to Reduce Lyme Disease Completed NCT00594997
41 Searching for Persistence of Infection in Lyme Disease Completed NCT01143558 Early Phase 1
42 Clinical Manifestations and Long-Term Outcome in Early Lyme Neuroborreliosis According to Diagnostic Certainty Completed NCT04653558
43 Comparison of Immunofluorescence Assay (IFA) and Chemiluminiscence Immunoassay (LIAISON®) for Diagnosis of Early Disseminated Lyme Borreliosis in Children, Younger Than 18 Years Completed NCT03798704
44 ImmuneSense Lyme Study Completed NCT04422314
45 Clinical Course, Serologic Response and Long-term Outcome in Elderly Patients With Early Lyme Borreliosis Completed NCT03371563 Antibiotics
46 Tick-Borne Encephalitis Virus and Lyme Borreliae Causing Coillness, Coinfection, or Just Coincidence. A Prospective Observational Study Completed NCT03958058 Anti-borrelial antibiotic therapy
47 Comparison of Two Culture Media for Cultivation of Borrelia Burgdorferi Sensu Lato Completed NCT02145754
48 Multicentre Clinical Trial to Assess the Performance of the DualDur In Vitro Diagnostic System in the Diagnosis of Lyme Borreliosis From Blood Samples of Subjects Who Are Either Pharmacotherapy-naive or Treatment-experienced and Their Physician Indicates Drug Therapy for Lyme Borreliosis Completed NCT03873974
49 Analysis of Erythema Migrans Lesions Completed NCT00132327
50 Doxycycline in Therapy of Erythema Migrans - do the Accompanying Symptoms Influence the Outcome? Completed NCT01475708 Doxycycline

Search NIH Clinical Center for Lyme Disease

Cochrane evidence based reviews: lyme disease

Genetic Tests for Lyme Disease

Anatomical Context for Lyme Disease

Organs/tissues related to Lyme Disease:

MalaCards : Heart, Spinal Cord, Skin, Eye, Brain, Whole Blood, Salivary Gland

Publications for Lyme Disease

Articles related to Lyme Disease:

(show top 50) (show all 13075)
# Title Authors PMID Year
1
Polyploidy, regular patterning of genome copies, and unusual control of DNA partitioning in the Lyme disease spirochete. 62 41
36450725 2022
2
Lyme borreliosis in Belgium: a cost-of-illness analysis. 62 41
36443755 2022
3
Cas9-mediated endogenous plasmid loss in Borrelia burgdorferi. 62 41
36441794 2022
4
Functional characterization of Borrelia spielmanii outer surface proteins that interact with distinct members of the human factor H protein family and with plasminogen. 53 62
19858303 2010
5
Complement factor H binding by different Lyme disease and relapsing fever Borrelia in animals and human. 53 62
19604355 2009
6
Identification and characterization of the factor H and FHL-1 binding complement regulator-acquiring surface protein 1 of the Lyme disease spirochete Borrelia spielmanii sp. nov. 53 62
18706858 2009
7
Prospective study of serologic tests for lyme disease. 53 62
18532885 2008
8
Subacute transverse myelitis with Lyme profile dissociation. 53 62
19675732 2008
9
Significantly improved accuracy of diagnosis of early Lyme disease by peptide enzyme-linked immunosorbent assay based on the borreliacidal antibody epitope of Borrelia burgdorferi OspC. 53 62
18417666 2008
10
Outer surface protein E antibody response and its effect on complement factor H binding to OspE in Lyme borreliosis. 53 62
18248762 2008
11
Binding of human complement regulators FHL-1 and factor H to CRASP-1 orthologs of Borrelia burgdorferi. 53 62
17160605 2006
12
Evidence that the BBA68 protein (BbCRASP-1) of the Lyme disease spirochetes does not contribute to factor H-mediated immune evasion in humans and other animals. 53 62
16622245 2006
13
Borrelia burgdorferi lipoprotein-mediated TLR2 stimulation causes the down-regulation of TLR5 in human monocytes. 53 62
16479520 2006
14
TLR2 expression in relation to IL-6 and IL-1beta and their natural regulators production by PMN and PBMC in patients with Lyme disease. 53 62
16864901 2006
15
Heterozygous Arg753Gln polymorphism of human TLR-2 impairs immune activation by Borrelia burgdorferi and protects from late stage Lyme disease. 53 62
16081826 2005
16
Improvement of Lyme borreliosis serodiagnosis by a newly developed recombinant immunoglobulin G (IgG) and IgM line immunoblot assay and addition of VlsE and DbpA homologues. 53 62
16081885 2005
17
Borreliacidal OspC antibodies specific for a highly conserved epitope are immunodominant in human lyme disease and do not occur in mice or hamsters. 53 62
15939749 2005
18
[Effect of rhIL-15 on TLR2 expression and apoptosis of PMN from patients with Lyme disease]. 53 62
16130298 2005
19
[Concentration of interleukin-18, interleukin-1beta, soluble receptor for interleukin-1 (sIL-1RII) and C-reactive protein in patients with neuroborreliosis]. 53 62
15735988 2005
20
Concentrations of macrophage inflammatory proteins MIP-1alpha and MIP-1beta and interleukin 8 (il-8) in lyme borreliosis. 53 62
15597225 2004
21
Diagnosis of Lyme neuroborreliosis with antibodies to recombinant proteins DbpA, BBK32, and OspC, and VlsE IR6 peptide. 53 62
14648148 2003
22
C-terminal region of outer surface protein C binds borreliacidal antibodies in sera from patients with Lyme disease. 53 62
12853388 2003
23
Serodiagnosis of Lyme disease by kinetic enzyme-linked immunosorbent assay using recombinant VlsE1 or peptide antigens of Borrelia burgdorferi compared with 2-tiered testing using whole-cell lysates. 53 62
12695997 2003
24
Increased expression of the Th1-inducing cytokines interleukin-12 and interleukin-18 in cerebrospinal fluid but not in sera from patients with Lyme neuroborreliosis. 53 62
12458049 2002
25
[Concentration of macrophage inflammatory proteins MIP-1 alpha and MIP-1 beta and interleukin 8 in erythema migrants]. 53 62
12362660 2002
26
[Lyme borreliosis--incidence of serum anti-myelin antibodies]. 53 62
11987581 2002
27
Species-specific serodiagnosis of Lyme arthritis and neuroborreliosis due to Borrelia burgdorferi sensu stricto, B. afzelii, and B. garinii by using decorin binding protein A. 53 62
11825956 2002
28
Recombinant flagellin A proteins from Borrelia burgdorferi sensu stricto, B. afzelii, and B. garinii in serodiagnosis of Lyme borreliosis. 53 62
11682523 2001
29
Recognition of multiple antibody epitopes throughout Borrelia burgdorferi p66, a candidate adhesin, in patients with early or late manifestations of Lyme disease. 53 62
11179382 2001
30
Downregulation of class II molecules on epidermal Langerhans cells in Lyme borreliosis. 53 62
11069457 2000
31
Reduced specificity of combined IgM and IgG enzyme immunoassay testing for lyme borreliosis. 53 62
10898148 2000
32
Evidence of Dbps (decorin binding proteins) among European strains of Borrelia burgdorferi sensu lato and in the immune response of LB patient sera. 53 62
10650211 2000
33
Utility of laboratory testing in autoimmune inner ear disease. 53 62
10569401 1999
34
Adherence of Borrelia burgdorferi. Identification of critical lysine residues in DbpA required for decorin binding. 53 62
10473582 1999
35
The Borrelia burgdorferi 37-kilodalton immunoblot band (P37) used in serodiagnosis of early lyme disease is the flaA gene product. 53 62
9986810 1999
36
The dominant epitope of Borrelia garinii outer surface protein C recognized by sera from patients with neuroborreliosis has a surface-exposed conserved structural motif. 53 62
9712750 1998
37
Comparison of immunodot and western blot assays for diagnosing Lyme borreliosis. 53 62
9665957 1998
38
Immunodiagnosis of human granulocytic ehrlichiosis by using culture-derived human isolates. 53 62
9620365 1998
39
Enzyme-linked immunosorbent assay using recombinant OspC and the internal 14-kDa flagellin fragment for serodiagnosis of early Lyme disease. 53 62
9542898 1998
40
Heat shock protein 70 of the agent of human granulocytic ehrlichiosis binds to Borrelia burgdorferi antibodies. 53 62
9455892 1998
41
Heterogeneity of BmpA (P39) among European isolates of Borrelia burgdorferi sensu lato and influence of interspecies variability on serodiagnosis. 53 62
9350727 1997
42
Simultaneous expression of Borrelia OspA and OspC and IgM response in cerebrospinal fluid in early neurologic Lyme disease. 53 62
9259573 1997
43
Temporal study of immunoglobin M seroreactivity to Borrelia burgdorferi in patients treated for Lyme borreliosis. 53 62
9041433 1997
44
Polymerase chain reaction detection of Lyme disease: correlation with clinical manifestations and serologic responses. 53 62
8623775 1996
45
Experimental immunization against Lyme borreliosis with recombinant Osp proteins: an overview. 53 62
8740122 1996
46
Increased cerebrospinal fluid levels of glial fibrillary acidic protein (GFAp) in Lyme neuroborreliosis. 53 62
8740104 1996
47
Use of recombinant antigens of Borrelia burgdorferi in serologic tests for diagnosis of lyme borreliosis. 53 62
8788993 1996
48
Establishment of enzyme-linked immunosorbent assay using purified recombinant 83-kilodalton antigen of Borrelia burgdorferi sensu stricto and Borrelia afzelii for serodiagnosis of Lyme disease. 53 62
8567889 1995
49
The outer surface proteins of Lyme disease borrelia spirochetes stimulate T cells to secrete interferon-gamma (IFN-gamma): diagnostic and pathogenic implications. 53 62
7664493 1995
50
A 55-kilodalton antigen encoded by a gene on a Borrelia burgdorferi 49-kilobase plasmid is recognized by antibodies in sera from patients with Lyme disease. 53 62
7642278 1995

Variations for Lyme Disease

Expression for Lyme Disease

Search GEO for disease gene expression data for Lyme Disease.

Pathways for Lyme Disease

Pathways related to Lyme Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 58)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.85 TNF TLR9 TLR7 TLR6 TLR2 TLR1
2
Show member pathways
13.81 C3 IFNB1 IL17A IL1B IL6 TLR1
3
Show member pathways
13.49 TNF TLR9 TLR7 TLR6 TLR2 TLR1
4
Show member pathways
13.44 CD40LG IL17A IL1B IL6 TLR1 TLR2
5
Show member pathways
13.33 TNF IL6 IL1B IL17A IFNB1 HLA-DRB1
6
Show member pathways
12.91 TNF TLR9 TLR7 TLR6 TLR2 TLR1
7
Show member pathways
12.73 CD40LG IL1B IL6 TLR1 TLR2 TLR6
8
Show member pathways
12.68 CD40LG IL1B TLR1 TLR2 TLR6 TLR7
9
Show member pathways
12.66 TLR2 CRP CFHR1 CFH C4A C3
10
Show member pathways
12.63 TNF TLR9 TLR2 IL6 IL1B
11 12.6 TNF TLR9 TLR7 TLR6 TLR2 TLR1
12
Show member pathways
12.46 TLR9 TLR7 TLR6 TLR2 TLR1
13
Show member pathways
12.31 TNF TLR9 TLR7 TLR6 TLR2 TLR1
14
Show member pathways
12.31 TNF TLR9 TLR7 TLR6 TLR2 TLR1
15
Show member pathways
12.3 TLR9 TLR7 TLR6 TLR2 TLR1 HSPD1
16
Show member pathways
12.29 TNF TLR2 IL6 IL17A
17 12.26 TNF TLR9 TLR7 TLR6 TLR2 TLR1
18 12.21 TNF IL6 IL1B HSPD1 C4A
19
Show member pathways
12.18 TNF IL17A IFNB1 HLA-DRB1 CD40LG
20
Show member pathways
12.17 TLR9 TLR7 TLR6 TLR2 TLR1 C3
21
Show member pathways
12.11 TLR9 TLR7 TLR6 TLR2 TLR1 IL1B
22
Show member pathways
12.02 CRP CFH C4A C3
23 11.99 TNF IL6 IL1B IL17A
24
Show member pathways
11.99 CRP CFH C4A C3
25
Show member pathways
11.96 TLR9 TLR7 TLR6 TLR2 IFNB1
26 11.92 C3 C4A CD40LG HLA-DRB1 IL17A IL1B
27
Show member pathways
11.83 CRP HLA-DRB1 IFNB1 IL6
28 11.82 TNF TLR9 TLR7 IL6 IL1B IFNB1
29 11.81 TNF IL6 IL1B IFNB1
30 11.8 TNF IL1B IL17A
31
Show member pathways
11.8 TNF IL1B IFNB1
32 11.73 IL6 IL1B IL17A
33
Show member pathways
11.72 TNF IL6 IL1B CD40LG
34 11.72 C3 C4A CD40LG CRP IL6 TLR7
35 11.71 TNF IL6 IL1B CD40LG
36 11.69 TNF IL6 IL1B
37 11.68 TNF TLR7 IL6
38
Show member pathways
11.65 TNF TLR2 IL6
40 11.58 TNF TLR7 IFNB1
41 11.58 TNF IL6 CD40LG
42 11.55 TNF TLR2 IL1B
43 11.54 TNF IL6 IL1B
44
Show member pathways
11.52 TLR9 TLR7 TLR6 TLR2 TLR1 IL6
45 11.51 TNF IL6 IL1B
46 11.49 TNF IL6 IFNB1
47 11.4 TNF IL6 IL1B IL17A
48 11.39 TNF IL6 IL1B
49 11.37 TNF IL6 IL1B IFNB1 HLA-DRB1
50 11.32 TNF IL6 IL1B

GO Terms for Lyme Disease

Cellular components related to Lyme Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.32 TNF TLR9 IL6 IL1B IL17A IFNB1
2 blood microparticle GO:0072562 9.92 CFHR1 CFH C4A C3
3 extracellular space GO:0005615 9.74 TNF IL6 IL1B IL17A IFNB1 HSPD1
4 Toll-like receptor 1-Toll-like receptor 2 protein complex GO:0035354 9.46 TLR1 TLR2
5 Toll-like receptor 2-Toll-like receptor 6 protein complex GO:0035355 9.26 TLR2 TLR6

Biological processes related to Lyme Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 60)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.6 C3 CD40LG HLA-DRB1 IL1B IL6 TLR1
2 positive regulation of gene expression GO:0010628 10.51 TNF TLR9 TLR6 TLR2 IL6 IL1B
3 innate immune response GO:0045087 10.45 C3 C4A CFH CRP IL17A TLR1
4 defense response to virus GO:0051607 10.4 TLR9 TLR7 TLR2 IL6 IFNB1
5 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 10.38 TNF TLR9 TLR6 IL1B HLA-DRB1
6 defense response to Gram-positive bacterium GO:0050830 10.33 TNF TLR2 IL6 IL1B IL17A CRP
7 positive regulation of inflammatory response GO:0050729 10.32 IL1B TLR2 TLR7 TLR9 TNF
8 positive regulation of tumor necrosis factor production GO:0032760 10.32 TLR9 TLR2 TLR1 IL6 IL17A
9 positive regulation of NF-kappaB transcription factor activity GO:0051092 10.29 TNF TLR9 TLR6 TLR2 IL6 IL1B
10 positive regulation of type II interferon production GO:0032729 10.28 TNF TLR9 TLR7 IL1B HSPD1
11 positive regulation of interleukin-1 beta production GO:0032731 10.26 TNF TLR6 IL6 IL17A
12 I-kappaB kinase/NF-kappaB signaling GO:0007249 10.26 TNF TLR9 TLR7 IL1B
13 positive regulation of NIK/NF-kappaB signaling GO:1901224 10.26 TNF TLR9 TLR7 TLR2 IL1B
14 humoral immune response GO:0006959 10.25 HLA-DRB1 IFNB1 IL6 TNF
15 positive regulation of interleukin-12 production GO:0032735 10.22 TLR9 TLR2 IL17A HSPD1 CD40LG
16 positive regulation of interleukin-10 production GO:0032733 10.21 TLR9 TLR2 IL6 HSPD1 CD40LG
17 regulation of insulin secretion GO:0050796 10.2 TNF IL6 IL1B
18 B cell proliferation GO:0042100 10.2 IFNB1 HSPD1 CD40LG
19 positive regulation of JUN kinase activity GO:0043507 10.2 TNF TLR9 TLR6
20 positive regulation of nitric oxide biosynthetic process GO:0045429 10.19 IL1B TLR6 TNF
21 positive regulation of interferon-beta production GO:0032728 10.19 TLR9 TLR7 TLR2
22 lipopolysaccharide-mediated signaling pathway GO:0031663 10.19 TNF TLR2 IL1B
23 complement activation GO:0006956 10.19 CFHR1 CFH C4A C3
24 positive regulation of vascular endothelial growth factor production GO:0010575 10.18 IL6 IL1B C3
25 negative regulation of neurogenesis GO:0050768 10.17 TNF IL6 IL1B
26 positive regulation of cytokine production involved in inflammatory response GO:1900017 10.17 IL17A IL6 TLR6 TNF
27 positive regulation of interferon-alpha production GO:0032727 10.16 TLR9 TLR7 HSPD1
28 toll-like receptor signaling pathway GO:0002224 10.16 TLR1 TLR2 TLR6 TLR7 TLR9
29 positive regulation of glial cell proliferation GO:0060252 10.14 TNF IL6 IL1B
30 immune system process GO:0002376 10.13 TLR9 TLR7 TLR6 TLR2 TLR1 IL17A
31 immune response GO:0006955 10.13 C3 CD40LG HLA-DRB1 IL17A IL1B IL6
32 I-kappaB phosphorylation GO:0007252 10.12 TLR9 TLR7 TLR2
33 microglial cell activation GO:0001774 10.12 TLR2 TLR6 TLR9 TNF
34 positive regulation of neuroinflammatory response GO:0150078 10.11 TNF IL6 IL1B
35 positive regulation of chemokine production GO:0032722 10.11 IL1B IL6 TLR2 TLR7 TLR9 TNF
36 negative regulation of lipid storage GO:0010888 10.1 TNF IL6 CRP
37 MyD88-dependent toll-like receptor signaling pathway GO:0002755 10.1 TLR9 TLR6 TLR2 TLR1 HSPD1
38 positive regulation of interleukin-8 production GO:0032757 10.1 TNF TLR9 TLR7 TLR2 TLR1 IL6
39 positive regulation of interleukin-18 production GO:0032741 10.09 TNF TLR9 TLR2
40 vascular endothelial growth factor production GO:0010573 10.08 TNF IL6 IL1B
41 cellular response to bacterial lipopeptide GO:0071221 10.08 TLR1 TLR2 TLR6
42 cell activation GO:0001775 10.08 TLR1 TLR2 TLR6 TNF
43 inflammatory response GO:0006954 10.05 C3 C4A CD40LG CRP IL17A IL1B
44 positive regulation of apoptotic cell clearance GO:2000427 10.02 C4A C3
45 positive regulation of oxidative stress-induced neuron death GO:1903223 10.02 TNF TLR6
46 positive regulation of fever generation GO:0031622 10.02 TNF IL1B
47 cellular response to diacyl bacterial lipopeptide GO:0071726 10.01 TLR6 TLR2
48 sequestering of triglyceride GO:0030730 10.01 IL1B TNF
49 positive regulation of toll-like receptor signaling pathway GO:0034123 10.01 TLR2 TLR9
50 positive regulation of T cell mediated immune response to tumor cell GO:0002842 10 HSPD1 HLA-DRB1

Molecular functions related to Lyme Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane signaling receptor activity GO:0004888 10.07 TLR9 TLR7 TLR6 TLR2 TLR1
2 pattern recognition receptor activity GO:0038187 9.8 TLR9 TLR7 TLR2
3 NAD(P)+ nucleosidase activity GO:0050135 9.73 TLR1 TLR2 TLR6
4 Toll-like receptor 2 binding GO:0035663 9.71 TLR6 TLR1
5 NAD+ nucleotidase, cyclic ADP-ribose generating GO:0061809 9.63 TLR1 TLR2 TLR6
6 cytokine activity GO:0005125 9.4 TNF IL6 IL1B IL17A IFNB1 CD40LG
7 lipopeptide binding GO:0071723 9.35 TLR6 TLR2 TLR1

Sources for Lyme Disease

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....